Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 157 articles:
HTML format

Single Articles

    July 2021
  1. CORTES J, Rugo HS, Guo Z, Karantza V, et al
    Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
    Lancet. 2021;398:24-25.

  2. MASUDA J, Ozaki Y, Hara F, Kitano S, et al
    Pembrolizumab plus chemotherapy in triple-negative breast cancer.
    Lancet. 2021;398:24.

    May 2021
  3. REICH K, Teixeira HD, de Bruin-Weller M, Bieber T, et al
    Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 20. pii: S0140-6736(21)00589.
    PubMed     Abstract available

  4. GUTTMAN-YASSKY E, Teixeira HD, Simpson EL, Papp KA, et al
    Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Lancet. 2021 May 20. pii: S0140-6736(21)00588.
    PubMed     Abstract available

  5. THYSSEN JP, Thomsen SF
    Treatment of atopic dermatitis with biologics and Janus kinase inhibitors.
    Lancet. 2021 May 20. pii: S0140-6736(21)00717.

    April 2021
  6. RUBEL D
    Nanobody cytokine blockers in psoriasis.
    Lancet. 2021;397:1523-1524.

  7. PAPP KA, Weinberg MA, Morris A, Reich K, et al
    IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Lancet. 2021;397:1564-1575.
    PubMed     Abstract available

  8. GRIFFITHS CEM, Armstrong AW, Gudjonsson JE, Barker JNWN, et al
    Lancet. 2021;397:1301-1315.
    PubMed     Abstract available

    February 2021
  9. LAMBRECHTS RA, Uyttenboogaart M, Drost G
    A vertebral artery halo sign indicates giant cell arteritis affecting the posterior circulation of the brain.
    Lancet. 2021;397:e6.

  10. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    PubMed     Abstract available

  11. REICH K, Papp KA, Blauvelt A, Langley RG, et al
    Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Lancet. 2021;397:487-498.
    PubMed     Abstract available

  12. GORDON KB, Foley P, Krueger JG, Pinter A, et al
    Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Lancet. 2021;397:475-486.
    PubMed     Abstract available

  13. HUANG WW, Feldman SR
    The next quantum leap forward? Bimekizumab for psoriasis.
    Lancet. 2021;397:446-448.

    January 2021
  14. HUDOWENZ O, Klemm P, Lange U, Mueller-Ladner U, et al
    Widespread soft tissue calcification in systemic sclerosis, polymyositis, and polyarthritis.
    Lancet. 2021;397:409.

  15. GHORESCHI K, Balato A, Enerback C, Sabat R, et al
    Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.
    Lancet. 2021 Jan 27. pii: S0140-6736(21)00184.
    PubMed     Abstract available

  16. CHEN L, Zhou M
    Must be sympathetic nervous system with unilateral facial flushing in harlequin syndrome.
    Lancet. 2021;397:318.

  17. SIMPSON EL, Bieber T, Thyssen JP, Valdez H, et al
    Abrocitinib for atopic dermatitis - Authors' reply.
    Lancet. 2021;397:196.

  18. UPPAL SK, Chat VS, Kearns DG, Wu JJ, et al
    Abrocitinib for atopic dermatitis.
    Lancet. 2021;397:195-196.

  19. CHAKRABORTY U, Chandra A
    Bitot's spots, dry eyes, and night blindness indicate vitamin A deficiency.
    Lancet. 2021;397:e2.

    December 2020
  20. LLEO A, Wang GQ, Gershwin ME, Hirschfield GM, et al
    Primary biliary cholangitis.
    Lancet. 2020;396:1915-1926.
    PubMed     Abstract available

  21. LAI VWY, Meher-Homji Z, Liu F, Sasadeusz J, et al
    Primary herpes simplex virus type 2 hepatitis diagnosed during laparoscopy.
    Lancet. 2020;396:e90.

  22. CORTES J, Cescon DW, Rugo HS, Nowecki Z, et al
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Lancet. 2020;396:1817-1828.
    PubMed     Abstract available

    November 2020
  23. ROSMARIN D, Butler K, Kuo F, Harris JE, et al
    Ruxolitinib cream for the treatment of vitiligo - Authors' reply.
    Lancet. 2020;396:1736.

  24. UPPAL SK, Kearns DG, Chat VS, Wu JJ, et al
    Ruxolitinib cream for the treatment of vitiligo.
    Lancet. 2020;396:1735-1736.

    Breast cancer radiation therapy.
    Lancet. 2020;396:1559.

  26. BRUNT AM, Haviland JS, Wheatley DA, Yarnold JR, et al
    Breast cancer radiation therapy - Authors' reply.
    Lancet. 2020;396:1559-1560.

  27. OFFERSEN BV, Overgaard J
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558.

  28. DOUEK M, De Silva-Minor S, Davies L, Jones B, et al
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558-1559.

    October 2020
  29. UDOMKARNJANANUN S, Puapatanakul P, Praditpornsilpa K
    Relapsing polychondritis associated with pauci-immune crescentic glomerulonephritis.
    Lancet. 2020;396:e63.

    September 2020
  30. OZPOLAT HT, Baran B, Akyuz F
    Skin lesions indicate cause of acute gastrointestinal bleeding: neurofibromatosis type 1.
    Lancet. 2020;396:e52.

  31. STERGIOU IE, Christoforou P, Sypsa G, Skoufias S, et al
    Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia.
    Lancet. 2020;396:853.

    Advancing immunotherapy for early-stage triple-negative breast cancer.
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31962.

  33. MITTENDORF EA, Zhang H, Barrios CH, Saji S, et al
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31953.
    PubMed     Abstract available

  34. ABIGNANO G, Mennillo GA, Lettieri G
    Foot ulcers in systemic sclerosis escape surgical amputation.
    Lancet. 2020;396:e29.

    August 2020
  35. CARDENAS-DE LA GARZA JA, Esquivel-Valerio JA, Arvizu-Rivera RI, Colunga-Pedraza PR, et al
    Flushing out a plasmacytoma in a patient with POEMS and AESOP syndromes.
    Lancet. 2020;396:e21.

  36. FREITAS PFS, Oliveira JM, Kater CE
    Crisis? What crisis? Abdominal pain and darkening skin in Addison's disease.
    Lancet. 2020;396:498.

  37. JAMIOLKOWSKI D, Muhleisen B, Muller S, Navarini AA, et al
    SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report.
    Lancet. 2020 Aug 13. pii: S0140-6736(20)31754.

  38. LANGAN SM, Irvine AD, Weidinger S
    Atopic dermatitis.
    Lancet. 2020;396:345-360.
    PubMed     Abstract available

    July 2020
  39. SIMPSON EL, Sinclair R, Forman S, Wollenberg A, et al
    Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2020;396:255-266.
    PubMed     Abstract available

  40. WEIDINGER S, Schreiber S
    Abrocitinib for atopic dermatitis: a step forward.
    Lancet. 2020;396:215-217.

  41. OBASI AI
    Equity in excellence or just another tax on Black skin?
    Lancet. 2020 Jul 23. pii: S0140-6736(20)31536.

  42. LAM RPK, Wong KW, Wan CK
    Allergic contact dermatitis and tracheobronchitis associated with repeated exposure to tear gas.
    Lancet. 2020 Jul 13. pii: S0140-6736(20)31560.

    First step in a new era for treatment of patients with vitiligo.
    Lancet. 2020;396:74-75.

  44. ROSMARIN D, Pandya AG, Lebwohl M, Grimes P, et al
    Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Lancet. 2020;396:110-120.
    PubMed     Abstract available

  45. SHAIGANY S, Gnirke M, Guttmann A, Chong H, et al
    An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19.
    Lancet. 2020 Jul 10. pii: S0140-6736(20)31526.

  46. GINSBURG O, Horton R
    A Lancet Commission on women and cancer.
    Lancet. 2020;396:11-13.

    June 2020
  47. ALLEN S, Cortina CS
    An unusual cause of breast hypertrophy: pseudoangiomatous stromal hyperplasia secondary to contraceptive implant.
    Lancet. 2020;395:1937.

  48. GUTZMER R, Stroyakovskiy D, Gogas H, Robert C, et al
    Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2020;395:1835-1844.
    PubMed     Abstract available

  49. RIBAS A
    Triple therapy for BRAF(V600)-mutated melanoma.
    Lancet. 2020;395:1814-1815.

  50. AHMED MA, Abdelnabi M, Almaghraby A, Elkafrawy FR, et al
    Neuropathy, encephalopathy, status epilepticus, and acute intermittent porphyria.
    Lancet. 2020;395:e101.

    May 2020
  51. MURRAY BRUNT A, Haviland JS, Wheatley DA, Sydenham MA, et al
    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
    Lancet. 2020;395:1613-1626.
    PubMed     Abstract available

  52. ZIMMER L, Livingstone E, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2020;395:1558-1568.
    PubMed     Abstract available

    Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
    Lancet. 2020;395:1524-1525.

  54. VERDONI L, Mazza A, Gervasoni A, Martelli L, et al
    An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.
    Lancet. 2020 May 13. pii: S0140-6736(20)31103.
    PubMed     Abstract available

    Psoriatic arthritis: still room for improvement.
    Lancet. 2020;395:1463-1465.

  56. MCINNES IB, Behrens F, Mease PJ, Kavanaugh A, et al
    Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    Lancet. 2020;395:1496-1505.
    PubMed     Abstract available

    April 2020
    Buruli ulcer: cured by 8 weeks of oral antibiotics?
    Lancet. 2020;395:1231-1232.

  58. PHILLIPS RO, Robert J, Abass KM, Thompson W, et al
    Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
    Lancet. 2020;395:1259-1267.
    PubMed     Abstract available

  59. KERSCHBAUMER A, Aletaha D
    Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?
    Lancet. 2020;395:1091-1093.

  60. MEASE PJ, Rahman P, Gottlieb AB, Kollmeier AP, et al
    Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Lancet. 2020;395:1126-1136.
    PubMed     Abstract available

  61. DEODHAR A, Helliwell PS, Boehncke WH, Kollmeier AP, et al
    Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Lancet. 2020;395:1115-1125.
    PubMed     Abstract available

    March 2020
  62. BOUJAN N, Geraud C
    Neuropsychiatric symptoms, skin disease, and weight loss: necrolytic migratory erythema and a glucagonoma.
    Lancet. 2020;395:985.

  63. SPRING LM, Wander SA, Andre F, Moy B, et al
    Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
    Lancet. 2020;395:817-827.
    PubMed     Abstract available

  64. KROWN SE, Moser CB, MacPhail P, Matining RM, et al
    Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
    Lancet. 2020 Mar 5. pii: S0140-6736(19)33222.
    PubMed     Abstract available

  65. FREEMAN EE, McMahon DE, Laker-Oketta M
    Time to address disparities in the standard of care for Kaposi sarcoma.
    Lancet. 2020 Mar 5. pii: S0140-6736(20)30473.

    February 2020
  66. DESGRANGES F, Coste AT, Wernly D, Dufour J, et al
    Immunosuppressed gardener pricked by roses grows Legionella longbeachae.
    Lancet. 2020;395:604.

  67. PERRETT KP, Peters RL
    Emollients for prevention of atopic dermatitis in infancy.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)33174.

  68. SKJERVEN HO, Rehbinder EM, Vettukattil R, LeBlanc M, et al
    Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)32983.
    PubMed     Abstract available

  69. CHALMERS JR, Haines RH, Bradshaw LE, Montgomery AA, et al
    Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)32984.
    PubMed     Abstract available

  70. EARL HM, Hiller L, Plummer C, Miles D, et al
    Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
    Lancet. 2020;395:492-493.

  71. GUO S, Tse G, Liu T
    Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Lancet. 2020;395:491-492.

  72. NASH P
    Inhibition of interleukins 17A and 17F in psoriatic arthritis.
    Lancet. 2020;395:395-396.

  73. LANE R
    Geraldine McGinty: leading light in US radiology.
    Lancet. 2020;395:407.

  74. RITCHLIN CT, Kavanaugh A, Merola JF, Schett G, et al
    Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
    Lancet. 2020;395:427-440.
    PubMed     Abstract available

    January 2020
  75. CHUMSRI S, Thompson EA
    Carryover effects of aromatase inhibitors in prevention.
    Lancet. 2020;395:91-92.

    Biosimilars: a new era in access to breast cancer treatment.
    Lancet. 2020;395:2.

    December 2019
  77. COLES CE, Bliss JM, Poortmans PM
    Accelerated partial breast irradiation: more questions than answers?
    Lancet. 2019;394:2127-2129.

  78. CUZICK J, Sestak I, Forbes JF, Dowsett M, et al
    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
    Lancet. 2019 Dec 11. pii: S0140-6736(19)32955.
    PubMed     Abstract available

  79. STIENSTRA Y, Beeres DT, Phillips R, Vonk M, et al
    The public health control of scabies: priorities for research and action.
    Lancet. 2019;394:2068.

  80. MIDDLETON J, Walker SL, House T, Head MG, et al
    Ivermectin for the control of scabies outbreaks in the UK.
    Lancet. 2019;394:2068-2069.

  81. VICINI FA, Cecchini RS, White JR, Arthur DW, et al
    Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32514.
    PubMed     Abstract available

  82. WHELAN TJ, Julian JA, Berrang TS, Kim DH, et al
    External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32515.
    PubMed     Abstract available

    October 2019
  83. THANGARAJU P, Venkatesan S
    A double blow for a patient with leprosy: a reversal reaction and an adverse drug reaction.
    Lancet. 2019;394:1450.

  84. ABDALLAH FW, Wijeysundera DN
    Anaesthetic interventions and long-term tumour recurrence.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32314.

  85. SESSLER DI, Pei L, Huang Y, Fleischmann E, et al
    Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32313.
    PubMed     Abstract available

  86. BRUINSTROOP E, Cairo I, Drillenburg P, van Dam PS, et al
    Hypothyroidism to Graves' disease and late appearance of pretibial myxoedema.
    Lancet. 2019;394:1364.

    September 2019
  87. SCHMIDT E, Kasperkiewicz M, Joly P
    Lancet. 2019;394:882-894.
    PubMed     Abstract available

  88. CHAYED Z, Kamaleswaran S, Bygum A
    A spot diagnosis! Aplasia cutis congenita in monozygotic twins.
    Lancet. 2019;394:868.

    August 2019
  89. BERAL V, Peto R, Pirie K, Reeves G, et al
    Menopausal hormone therapy and 20-year breast cancer mortality.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)32033.

  90. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31709.
    PubMed     Abstract available

    Menopausal hormones: definitive evidence for breast cancer.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31901.

    People with albinism in Africa: contending with skin cancer.
    Lancet. 2019;394:553-554.

  93. REICH K, Armstrong AW, Langley RG, Flavin S, et al
    Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Lancet. 2019 Aug 8. pii: S0140-6736(19)31773.
    PubMed     Abstract available

  94. MAHIL SK, Smith CH
    Psoriasis biologics: a new era of choice.
    Lancet. 2019 Aug 8. pii: S0140-6736(19)31772.

  95. CHAPPELL LC, Bell JL, Smith A, Linsell L, et al
    Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
    Lancet. 2019 Aug 1. pii: S0140-6736(19)31270.
    PubMed     Abstract available

    July 2019
  96. ENGELMAN D, Cantey PT, Marks M, Solomon AW, et al
    The public health control of scabies: priorities for research and action.
    Lancet. 2019;394:81-92.
    PubMed     Abstract available

  97. THOMPSON JF, Friedman EB
    Appropriate excision margins for cutaneous melanomas.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31272.

    Interleukin-23 blockade: another breakthrough in the treatment of psoriasis.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31513.

  99. REICH K, Gooderham M, Thaci D, Crowley JJ, et al
    Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)30952.
    PubMed     Abstract available

  100. UTJES D, Malmstedt J, Teras J, Drzewiecki K, et al
    2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31132.
    PubMed     Abstract available

    June 2019
    Is the duration of adjuvant trastuzumab debate still clinically relevant?
    Lancet. 2019;393:2565-2567.

  102. DROLET M, Benard E, Perez N, Brisson M, et al
    Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Lancet. 2019 Jun 26. pii: S0140-6736(19)30298.
    PubMed     Abstract available

  103. QIAN YT, Ma DL
    Atypical presentation of classic Kaposi's sarcoma.
    Lancet. 2019;393:2521.

  104. PIVOT X, Romieu G, Debled M, Pierga JY, et al
    6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30653.
    PubMed     Abstract available

  105. EARL HM, Hiller L, Vallier AL, Loi S, et al
    6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30650.
    PubMed     Abstract available

    March 2019
  106. MCCRINDLE BW, Rowley AH
    Improving coronary artery outcomes for children with Kawasaki disease.
    Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.

  107. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
    Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
    Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
    PubMed     Abstract available

  108. ABDOLI A
    Lancet. 2019;393:872.

  109. BURZA S, Croft SL, Boelaert M
    Leishmaniasis - Authors' reply.
    Lancet. 2019;393:872-873.

  110. DEPAQUIT J, Gay F, Kaltenbach ML
    Lancet. 2019;393:871-872.

  111. SAURABH S
    Lancet. 2019;393:871.

    February 2019
  112. MUTEBI M
    Africa rising: gendered journeys of women patients and providers.
    Lancet. 2019;393:517-518.

    Dose intensification of chemotherapy for early breast cancer in the age of de-escalation.
    Lancet. 2019 Feb 7. pii: S0140-6736(19)30197.

  114. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
    Lancet. 2019 Feb 7. pii: S0140-6736(18)33137.
    PubMed     Abstract available

  115. MOSE KF, Bygum A
    Chinese herbal remedy found to contain steroids and antifungals.
    Lancet. 2019;393:446.

    January 2019
  116. GILHAR A, Keren A, Paus R
    JAK inhibitors and alopecia areata.
    Lancet. 2019;393:318-319.

  117. POWER SP, O'Mahony D
    Diffuse large vessel giant cell arteritis found by (18)Fluorodeoxyglucose PET/CT imaging.
    Lancet. 2019;393:349.

    December 2018
  118. CAMERON DA, Gelber RD, Procter M, Suter T, et al
    Concerns about cardiotoxicity in the HERA trial - Authors' reply.
    Lancet. 2018;390:2767-2768.

  119. LEVY A, Chargari C, Deutsch E, Rivera S, et al
    Concerns about cardiotoxicity in the HERA trial.
    Lancet. 2018;390:2767.

  120. MEASE P, Coates LC, Helliwell PS, Stanislavchuk M, et al
    Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
    Lancet. 2018;392:2367-2377.
    PubMed     Abstract available

    October 2018
  121. MAYA Y, Tashimo A, Ota M
    Persistent red and swollen eyelids.
    Lancet. 2018;392:1552.

    Ustekinumab: a promising new drug for SLE?
    Lancet. 2018;392:1284-1286.

    A new powerful drug to combat river blindness.
    Lancet. 2018;392:1170-1172.

  124. OPOKU NO, Bakajika DK, Kanza EM, Howard H, et al
    Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
    Lancet. 2018;392:1207-1216.
    PubMed     Abstract available

    September 2018
  125. SCHADENDORF D, van Akkooi ACJ, Berking C, Griewank KG, et al
    Lancet. 2018;392:971-984.
    PubMed     Abstract available

  126. LEBWOHL B, Sanders DS, Green PH
    Coeliac disease and dermatitis herpetiformis - Authors' reply.
    Lancet. 2018;392:917.

  127. RODRIGUES F, Bachmeyer C
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916.

  128. CAIO G, De Giorgio R, Volta U
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916-917.

  129. JANARTHANAN M, Rathinasamy J
    Aortic calcification in longstanding, undiagnosed Takayasu arteritis.
    Lancet. 2018;392:950.

    August 2018
  130. LA PLACA M, Chessa MA
    Erythema multiforme major with swollen lips and crusted erosions.
    Lancet. 2018;392:592.

  131. BURZA S, Croft SL, Boelaert M
    Lancet. 2018 Aug 17. pii: S0140-6736(18)31204.
    PubMed     Abstract available

  132. WILLER H
    Breast cancer in Venezuela: back to the 20th century.
    Lancet. 2018;392:461-462.

  133. CLINE A, Feldman SR
    Risankizumab for psoriasis.
    Lancet. 2018 Aug 7. pii: S0140-6736(18)31781.

  134. GORDON KB, Strober B, Lebwohl M, Augustin M, et al
    Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Lancet. 2018 Aug 7. pii: S0140-6736(18)31713.
    PubMed     Abstract available

    July 2018
  135. WALLACE DJ, Furie RA, Tanaka Y, Kalunian KC, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2018;392:222-231.
    PubMed     Abstract available

    June 2018
  136. LIU XK, Li J
    Acral lentiginous melanoma.
    Lancet. 2018;391:e21.

  137. SHEIKH S, Sasieni P
    When should the errors in the UK's breast screening programme have been spotted?
    Lancet. 2018;391:2319-2320.

  138. DEODHAR A, Gottlieb AB, Boehncke WH, Dong B, et al
    Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Lancet. 2018;391:2213-2224.
    PubMed     Abstract available

  139. NASH P
    Psoriatic arthritis: novel targets add to a therapeutic renaissance.
    Lancet. 2018;391:2187-2189.

    Psoriatic arthritis: classification and holistic management.
    Lancet. 2018;391:2185.

  141. VAN DEN BOSCH F, Coates L
    Clinical management of psoriatic arthritis.
    Lancet. 2018;391:2285-2294.
    PubMed     Abstract available

  142. VEALE DJ, Fearon U
    The pathogenesis of psoriatic arthritis.
    Lancet. 2018;391:2273-2284.
    PubMed     Abstract available

  143. ZOU Y, Hu W, Zheng J, Pan M, et al
    Nail infestation: an atypical presentation of typical scabies.
    Lancet. 2018;391:2272.

    April 2018
  144. MITJA O, Godornes C, Houinei W, Kapa A, et al
    Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study.
    Lancet. 2018;391:1599-1607.
    PubMed     Abstract available

  145. RIEDL MA, Relan A, Harper JR, Cicardi M, et al
    C1 esterase inhibitor concentrates and attenuated androgens - Authors' reply.
    Lancet. 2018;391:1356.

  146. MULLER YD, Harr T, Dayer E, Seebach JD, et al
    C1 esterase inhibitor concentrates and attenuated androgens.
    Lancet. 2018;391:1355-1356.

    February 2018
  147. SMAJS D, Pospisilova P
    Macrolide resistance in yaws.
    Lancet. 2018 Feb 7. pii: S0140-6736(18)30205.

    January 2018
  148. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
    Targeted radiotherapy for early breast cancer.
    Lancet. 2018;391:26-27.

    October 2017
  149. AERTS O, Herman A, Bruze M, Goossens A, et al
    FreeStyle Libre: contact irritation versus contact allergy.
    Lancet. 2017;390:1644.

    July 2017
  150. SCHMITT AR, Wetter DA, Camilleri MJ, Khan SP, et al
    Langerhans cell histiocytosis presenting as a blueberry muffin rash.
    Lancet. 2017;390:155.

    June 2017
  151. MEASE P
    New pathways of treatment for psoriatic arthritis.
    Lancet. 2017;389:2268-2270.

    February 2017
  152. SPECHT JM, Davidson NE
    Optimal duration of trastuzumab for early HER2-positive breast cancer.
    Lancet. 2017 Feb 16. pii: S0140-6736(17)30322.

  153. CAMERON D, Piccart-Gebhart MJ, Gelber RD, Procter M, et al
    11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Lancet. 2017 Feb 16. pii: S0140-6736(16)32616.
    PubMed     Abstract available

  154. PARES A
    An appealing new agent for treating cholestatic pruritus.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30320.

  155. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
    PubMed     Abstract available

    December 2016
  156. NATSUME O, Kabashima S, Nakazato J, Yamamoto-Hanada K, et al
    Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2016 Dec 7. pii: S0140-6736(16)31418.
    PubMed     Abstract available

    November 2016
  157. HARBECK N, Gnant M
    Breast cancer.
    Lancet. 2016 Nov 16. pii: S0140-6736(16)31891.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.